权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

PDE4D Allosteric Modulators for Treating Cognitive Impairment

用于治疗认知障碍的 PDE4D 变构调节剂

基本信息

批准号：
9068253
负责人：
Mark E Gurney
金额：
--
依托单位：
TETRA DISCOVERY PARTNERS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-06-15 至 2016-07-19
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9068253
关键词：
Activities of Daily Living Address Adult Affect Aftercare Alzheimer&apos s Disease Amyloid beta-Protein Aricept Binding Biochemical Biological Assay Biological Availability Biological Markers Boxing Brain CREB1 gene Central Nervous System Diseases Cholinesterase Inhibitors Clinical Clinical Trials Clinical dementia rating scale Cocrystallography Cognition Cognitive Collaborations Cyclic AMP-Dependent Protein Kinases Cytochrome P450 Dementia Demographic Aging Dendritic Spines Deposition Developed Countries Diagnostic Dimensions Dose Drug Targeting Elderly Enrollment Functional disorder Funding Generations Goals Health Hepatocyte Hippocampus (Brain)Human Impaired cognition In Vitro Individual Knowledge Lead Life Long-Term Potentiation Measures Medical Memory Mental Depression Metabolic Activation Metabolism Modeling Monkeys Morphology National Institute on Aging Oral Outcome Paired-Associate Learning Pathology Pathway interactions Patients Peptides Persons Pharmaceutical Preparations Phase Phase III Clinical Trials Plasma Population Prevention Property Publishing Recommendation Retrieval Rodent Rolipram Sales Senile Plaques Short-Term Memory Solubility Structure Sum System Therapeutic Toxic effect United States National Institutes of Health Vomiting base cerebral atrophy clinical research site clinically significant cognitive function cognitive testing cooperative study coping design drug market experience genotoxicity impression improved in vivo inhibitor/antagonist instrument member mental state mild cognitive impairment mouse model neurochemistry neuroimaging neuron loss phase III trial phosphodiesterase 4D phosphoric diester hydrolase pre-clinical programs scaffold screening synaptic function working group

项目摘要

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is an increasing medical burden due to the aging demographics of the US population. The most common form of dementia among older adults, AD affects parts of the brain important for memory formation and retrieval, seriously impairing a person's ability to live independently and cope with daily activities. In collaboration with the NIH Blueprint Neurotherapeutics Program, we seek to develop phosphodiesterase Type 4 (PDE4) allosteric modulators for improving cognition in accordance with the Target Product Profile below. Ideally, the therapeutic will improve cognition in MCI patients and impact AD pathophysiology, thereby slowing conversion to probable AD. Drug PropertiesMinimum Acceptable ResultIdeal ResultPrimary Drug IndicationImprovement of cognition in persons with Mild Cognitive Impairment (MCI) due to probable ADSlowing of conversion from MCI to probable ADPatient PopulationPatients with MCI due to probable AD according to the NIAA/AA working group criteriaPatients with MCI due to probable AD according to the NIAA/AA working group criteriaDelivery ModeOralOralTreatment DurationChronicChronicRegimenOral, once dailyOral, once daily

描述（由申请人提供）：由于美国人口的老龄化，阿尔茨海默病（AD）是一种日益增加的医疗负担。AD是老年人中最常见的痴呆症形式，它影响大脑中对记忆形成和检索至关重要的部分，严重损害一个人独立生活和科普日常活动的能力。与NIH蓝图神经治疗计划合作，我们寻求开发磷酸二酯酶4型（PDE 4）变构调节剂，用于根据以下目标产品简介改善认知。理想情况下，治疗将改善MCI患者的认知并影响AD病理生理学，从而减缓向可能AD的转化。药物性质最低可接受结果理想结果主要药物适应症改善可能由AD引起的轻度认知障碍（MCI）患者的认知减缓从MCI向可能AD的转化患者人群根据NIAA/AA工作组标准，可能由AD引起的MCI患者根据NIAA/AA工作组标准，可能由AD引起的MCI患者给药方式口服口服治疗持续时间慢性慢性方案口服，每日一次口服，每日一次